VPC
RCUS icon

Vestal Point Capital’s Arcus Biosciences RCUS Stock Holding History

Vestal Point Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250,000
Closed -$3.4M – 101
2025
Q3 		$3.4M Buy
+250,000
New +$2.6M 0.15% 71

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vestal Point Capital's RCUS Position: Q4 2025 in Review

Vestal Point Capital sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 250,000 shares — an estimated $3.4M sold.

Vestal Point Capital first reported a position in RCUS in Q3 2025 and held it in 1 quarter. The position peaked at $3.4M in Q3 2025. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • Vestal Point Capital reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • Vestal Point Capital sold 250,000 Arcus Biosciences shares in Q4 2025, an estimated $3.4M.
  • Vestal Point Capital first reported a position in Arcus Biosciences in Q3 2025 and held it in 1 quarter.
  • Vestal Point Capital's Arcus Biosciences position peaked at $3.4M in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.